CD79 (AA 202-216) Antikörper

Produktnummer ABIN7872078

Der Maus Monoklonal anti-CD79 Antikörper wird verwendet zum Nachweis von CD79 in Proben von Human. Er wurde validiert für IHC (p).

Kurzübersicht für CD79 (AA 202-216) Antikörper (ABIN7872078)

Target: CD79

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Unkonjugiert

Applikation: Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Klon: SPM549

Produktdetails

Bindungsspezifität: AA 202-216

Verwendungszweck: CD79 Antibody

Aufreinigung: Protein G affinity chromatography

Immunogen: Amino acids 202-216 (GTYQDVGSLNIADVQ-human) from the alpha chain were used as the immunogen for this CD79 antibody.

Isotyp: IgG1, kappa

Anwendungsinformationen

Applikationshinweise: The optimal dilution of the CD79 antibody for each application should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in pH 9 10 mM Tris with 1 mM EDTA for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Prediluted in 1X PBS, 0.1 mg/mL BSA (US sourced), 0.05 % sodium azide, *For IHC use only*

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the CD79 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).

Antigendetails

Target: CD79

Hintergrund: A disulphide-linked heterodimer, consisting of mb-1 (or CD79a) and B29 (or CD79b) polypeptides, is non-covalently associated with membrane-bound immunoglobulins on B cells. This complex of mb-1 and B29 polypeptides and immunoglobulin constitute the B cell Ag receptor. CD79a first appears at pre B cell stage, early in maturation, and persists until the plasma cell stage where it is found as an intracellular component. CD79a is found in the majority of acute leukemias of precursor B cell type, in B cell lines, B cell lymphomas, and in some myelomas. It is not present in myeloid or T cell lines. Anti-CD79a is generally used to complement anti-CD20 especially for mature B-cell lymphomas after treatment with Rituximab (anti-CD20). This antibody will stain many of the same lymphomas as anti-CD20, but also is more likely to stain B-lymphoblastic lymphoma/leukemia than is anti-CD20. Anti-CD79a also stains more cases of plasma cell myeloma and occasionally some types of endothelial cells as well.

UniProt: P11912